AstraZeneca gets import & marketing approval for Durvalumab in India
Category: #health  By Dhananjay Punekar  Date: 2018-06-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca gets import & marketing approval for Durvalumab in India

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab cite reports. Authentic sources claim that the drug is used to treat patients affected due to advanced & unresectable non-small cell lung cancer (NSCLC) and metastatic urothelial carcinoma.

Durvalumab, also known by the name of ImfinziTM is a patented drug of AstraZeneca Global and is a part of a new class of immunotherapy medicines also referred as checkpoint inhibitors

Business Standard has reported that Durvalumab had received the status of ‘breakthrough therapy” from the U.S. Food & Drug Agency on 31st July 2017. Reports claim that in February this year, the U.S. regulatory body had approved the drug for treating unresectable stage III non-small cell lung cancer.

Reportedly, the market price of the firm’s stocks increased by 5% and hit INR 1,416 in the early morning trade after AstraZeneca announced the approval of its drug from the Indian drug regulator. AstraZeneca Pharma has also emphasized that the approval of Durvalumab has facilitated the firm to introduce the drug in the country, subject to related statutory approvals & licenses.

Gagan Singh, MD of AstraZeneca Pharma India, has stated that receiving the import & market permission for Durvalumab to treat both NSCLC in its third stage and metastatic urothelial carcinoma is a landmark for patients having limited cancer treatment alternatives.

He further added that the country houses nearly one-third of the patient population affected from stage three NSCLC and amidst this grim scenario, AstraZeneca is happy to bring forth the first immunotherapy for NSCLC patients.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...

Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes
Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes
By Dhananjay Punekar

Kallyope Inc., a platform biotech company, and Novo Nordisk A/S, a Denmark based healthcare firm, have declared that they have both signed an option agreement for jointly carrying out research programs to discover new ...